Lilly's New Obesity Pill Foundayo Poised for Multi-Billion Dollar Debut, Analysts Project
LLY sits 51% above its 52-week low of $623.78 on elevated volume (2.0× avg).
Summary
Wall Street analysts are projecting a multi-billion dollar debut for Eli Lilly's newly FDA-approved oral obesity pill, Foundayo (orforglipron). Estimates for 2026 sales range from $1.5 billion to $2.8 billion, with some analysts forecasting peak annual sales potentially exceeding $40 billion. This news provides crucial financial context following yesterday's FDA approval of Foundayo. These projections indicate a highly material new revenue stream for Eli Lilly, positioning the drug as a strong challenger to Novo Nordisk in the rapidly expanding oral obesity treatment market, particularly given its easier manufacturing and fewer dosing restrictions. Traders will closely monitor early uptake and weekly new-patient starts, as initial launch dynamics could temper near-term revenue despite strong long-term prescription volume expectations.
At the time of this announcement, LLY was trading at $942.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $901.8B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.